Restricted accessResearch articleFirst published online 2023-02
Graft-Versus-Host-Disease and Health-Related Quality of Life in Young Long-term Survivors of Cancer and Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an established treatment predominantly for malignancies. Chronic graft-versus-host disease (cGVHD) is the leading long-term complication after allo-HSCT, but knowledge on cGVHD and health-related quality of life (HRQOL) in long-term survivors of allo-HSCT performed in childhood, adolescence, and young adulthood (CAYA) is scarce.
Therefore, we aimed to (1) assess prevalence and risk factors of active cGVHD using the 2014 National Institutes of Health-Consensus criteria, (2) investigate associations between cGVHD severity, patient-reported symptom burden, and HRQOL, and (3) compare HRQOL of survivors to population norms.
Methods:
We conducted a nationwide cross-sectional study in long-term survivors of CAYA allo-HSCT combining clinical examinations and patient-reported outcome measures.
Results:
We included 103 survivors, 55 (53%) females, median age of 19.6 years [range 0.3–29.9] at HSCT, 16.8 years [6.0–32.0] from HSCT, and 77 (75%) with underlying malignancy. Overall, 32 (31%) survivors were diagnosed with active cGVHD. The risk of active cGVHD was increased with prior acute GVHD and reduced with in vivo T cell depletion. cGVHD severity was associated with increased symptom burden, but not with adverse HRQOL. Compared to Norwegian population norms, allo-HSCT survivors reported significantly lower HRQOL.
Conclusion:
These results indicate a high prevalence of cGVHD in long-term survivors of CAYA allo-HSCT. Although we did not find an association between cGVHD severity and HRQOL, survivors reported significantly poorer HRQOL compared to population norms. Knowledge on the long-term consequences of cGVHD will be important for optimizing treatment and long-term follow-up care after CAYA allo-HSCT.
Get full access to this article
View all access options for this article.
References
1.
LeeSJ, FlowersME. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2008: 134–41. DOI: 10.1182/asheducation-2008.1.134.
2.
ArmenianSH, SunCL, KawashimaT, et al.Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood. 2011; 118(5):1413–20.
3.
BhatiaS, FranciscoL, CarterA, et al.Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007; 110(10):3784–92.
4.
EissaHM, LuL, BaassiriM, et al.Chronic disease burden and frailty in survivors of childhood HSCT: a report from the St. Jude Lifetime Cohort Study. Blood Adv. 2017; 1(24):2243–46.
5.
MartinPJ, CountsGWJr., AppelbaumFR, et al.Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010; 28(6):1011–16.
6.
PidalaJ, AnasettiC, JimH. Quality of life after allogeneic hematopoietic cell transplantation. Blood. 2009; 114(1):7–19.
7.
PidalaJ, KurlandB, ChaiX, et al.Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011; 117(17):4651–7.
8.
SunCL, FranciscoL, KawashimaT, et al.Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood. 2010; 116(17):3129–39;quiz 3377.
9.
AraiS, AroraM, WangT, et al.Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015; 21(2):266–74.
10.
EapenM, HorowitzMM, KleinJP, et al.Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol. 2004; 22(24):4872–80.
StewartBL, StorerB, StorekJ, et al.Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004; 104(12):3501–6.
13.
InagakiJ, MoritakeH, NishikawaT, et al.Long-term morbidity and mortality in children with chronic graft-versus-host disease classified by National Institutes of Health consensus criteria after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015; 21(11):1973–80.
14.
LeeSJ.Classification systems for chronic graft-versus-host disease. Blood. 2017; 129(1):30–7.
15.
FilipovichAH, WeisdorfD, PavleticS, et al.National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11(12):945–56.
16.
ShulmanHM, SullivanKM, WeidenPL, et al.Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980; 69(2):204–17.
17.
JagasiaMH, GreinixHT, AroraM, et al.National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015; 21(3):389–401.e381.
18.
EapenM, LoganBR, AppelbaumFR, et al.Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. Biol Blood Marrow Transplant. 2015; 21(1):55–9.
19.
MajhailNS, TaoL, BredesonC, et al.Prevalence of hematopoietic cell transplant survivors in the United States. Biol Blood Marrow Transplant. 2013; 19(10):1498–501.
20.
FrommeEK, EilersKM, MoriM, et al.How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol. 2004; 22(17):3485–90.
21.
OvretveitJ, ZubkoffL, NelsonEC, et al.Using patient-reported outcome measurement to improve patient care. Int J Qual Health Care. 2017; 29(6):874–9.
22.
KerepAZ, BroomeJ, PirslF, et al.Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients. Bone marrow Transplant. 2019; 54(1):76–84.
23.
LeeSJ, WolffD, KitkoC, et al.Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015; 21(6):984–99.
24.
ReeveBB, MitchellSA, DueckAC, et al.Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J Natl Cancer Inst. 2014; 106(7):1–8.
25.
AldenhovenM, WynnRF, OrchardPJ, et al.Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015; 125(13):2164–72.
26.
GlucksbergH, StorbR, FeferA, et al.Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974; 18(4):295–304.
27.
TehC, OnstadL, LeeSJ. Reliability and validity of the modified 7-day lee chronic graft-versus-host disease symptom scale. Biol Blood Marrow Transplant. 2020; 26(3):562–7.
28.
LogeJH, KaasaS. Short form 36 (SF-36) health survey: normative data from the general Norwegian population. Scand J Soc Med. 1998; 26(4):250–8.
29.
WareJ, SnowKK, KosinskiM, GandekB. SF-36 health survey. Manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993; pp. 10.16–10.17.
30.
HopmanWM, BergerC, JosephL, et al.The natural progression of health-related quality of life: results of a five-year prospective study of SF-36 scores in a normative population. Qual Life Res. 2006; 15(3):527–36.
31.
JacobsenEL, ByeA, AassN, et al.Norwegian reference values for the Short-Form Health Survey 36: development over time. Qual Life Res. 2018; 27(5):1201–12.
32.
CuvelierGDE, NemecekER, WahlstromJT, et al.Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria. Blood. 2019; 134(3):304–16.
33.
JacobsohnDA, AroraM, KleinJP, et al.Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease. Blood. 2011; 118(16):4472–79.
34.
ZeccaM, PreteA, RondelliR, et al.Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood. 2002; 100(4):1192–200.
35.
AroraM, CutlerCS, JagasiaMH, et al.Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016; 22(3):449–55.
36.
BairdK, SteinbergSM, GrkovicL, et al.National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis. Biol Blood Marrow Transplant. 2013; 19(4):632–9.
37.
GrubeM, HollerE, WeberD, et al.Risk factors and outcome of chronic graft-versus-host disease after allogeneic stem cell transplantation-results from a single-center observational study. Biol Blood Marrow Transplant. 2016; 22(10):1781–91.
38.
PathakM, DiepPP, LaiX, et al.Ocular findings and ocular graft-versus-host disease after allogeneic stem cell transplantation without total body irradiation. Bone Marrow Transplant. 2018; 53(7):863–72.
39.
BerbisJ, MichelG, ChastagnerP, et al.A French cohort of childhood leukemia survivors: impact of hematopoietic stem cell transplantation on health status and quality of life. Biol Blood Marrow Transplant. 2013; 19(7):1065–72.
40.
FlowersME, InamotoY, CarpenterPA, et al.Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011; 117(11):3214–19.
41.
DelbosF, BarhoumiW, CabanneL, et al.Donor immunization against human leukocyte class II antigens is a risk factor for graft-versus-host disease. Biol Blood Marrow Transplant. 2016; 22(2):292–9.
42.
KrogerN, SolanoC, WolschkeC, et al.Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016; 374(1):43–53.
43.
KrupskiC, JagasiaM. Quality of life in the chronic GVHD Consortium Cohort: lessons learned and the long road ahead. Curr Hematol Malig Rep. 2015; 10(3):183–91.
44.
LeeS, CookEF, SoifferR, AntinJH. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2002; 8(8):444–52.
45.
MerkelEC, MitchellSA, LeeSJ. Content validity of the lee chronic graft-versus-host disease symptom scale as assessed by cognitive interviews. Biol Blood Marrow Transplant. 2016; 22(4):752–8.
46.
CurtisLM, DatilesMB, 3rd, SteinbergSM, et al.Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice. Haematologica. 2015; 100(9):1228–36.
47.
ReinfjellT, TremoladaM, ZeltzerLK. A review of demographic, medical, and treatment variables associated with health-related quality of life (HRQOL) in survivors of hematopoietic stem cell (HSCT) and bone marrow transplantation (BMT) during childhood. Front Psychol. 2017; 8:253.
48.
KurosawaS, OshimaK, YamaguchiT, et al.Quality of life after allogeneic hematopoietic cell transplantation according to affected organ and severity of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017; 23(10):1749–58.
49.
InamotoY, MartinPJ, ChaiX, et al.Clinical benefit of response in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2012; 18(10):1517–24.
50.
SprangersMA, SchwartzCE. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med. 1999; 48(11):1507–15.
51.
ClarkeSA, SkinnerR, GuestJ, et al.Clinical outcomes and health-related quality of life (HRQOL) following haemopoietic stem cell transplantation (HSCT) for paediatric leukaemia. Child Care Health Dev. 2011; 37(4):571–80.
52.
SandersJE, HoffmeisterPA, StorerBE, et al.The quality of life of adult survivors of childhood hematopoietic cell transplant. Bone Marrow Transplant. 2010; 45(4):746–54.
53.
SchultzKA, ChenL, ChenZ, et al.Health conditions and quality of life in survivors of childhood acute myeloid leukemia comparing post remission chemotherapy to BMT: a report from the children's oncology group. Pediatr Blood Cancer. 2014; 61(4):729–36.
54.
BarreraM, GeeC, AndrewsGS, et al.Health-related quality of life of children and adolescents prior to hematopoietic progenitor cell transplantation: diagnosis and age effects. Pediatr Blood Cancer. 2006; 47(3):320–26.
55.
LieHC, RueeggCS, FossaSD, et al.Limited evidence of non-response bias despite modest response rate in a nationwide survey of long-term cancer survivors-results from the NOR-CAYACS study. J Cancer Surviv. 2019; 13(3):353–63.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
